ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

Glioblastoma (GBM) creates an immunosuppressive environment that presents a challenge to efficacy of immunotherapeutic approaches. Results from the CheckMate-143 trial demonstrated responses in 8% of patients with nivolumab, underscoring the need for further insight into the mechanisms and markers o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Ahluwalia, Manmeet, Grabowski, Matthew, Alban, Tyler, Otvos, Balint, Bayik, Defne, Saeed Bamashmos, Anas, Rayman, Patricia, Diaz-Montero, Marcela, Reardon, David, Wen, Patrick, Peereboom, David, Lathia, Justin
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Adult Clinical Trials–Immunologic
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847386/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.039
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki